• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Spark Therapeutics Appoints CTO

    Cryoport Launches ESG Program

    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail

    Thermo Fisher Scientific Completes Mesa Biotech Acquisition

    Ashfield Engage, Popit Form Digital Monitoring Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Solid Dose Market Trends

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Almac Group

    Alcami

    test company saurabh

    PCI Pharma Services

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Adare Pharma Solutions

    Aphena Pharma Solutions

    Syngene

    Reed-Lane

    PCI Pharma Services
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Bio News & Views

    Future Bio-Capacity Constraints

    Top 10 factors from a new survey

    Related CONTENT
    • Opportunities in Synthetic Biology
    • eTheRNA Extends mRNA Production Services
    • Vetio Animal Health
    • Current Trends in Analytical Testing
    • CMOs & Biosimilars Mfg. in the U.S.
    Eric S. Langer, BioPlan Associates, Inc.09.06.12
    Capacity constraints in biomanufacturing, although far less impactful than what was occurring 10 years ago, continue to affect the industry in different ways. Today, at least two-thirds of biomanufacturers are facing at least minor constraints at clinical and commercial stages of manufacturing. This is according to data released in our 9th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production. Further, the 302 biotherapeutic developers and contract manufacturing organizations (CMOs) we surveyed this year don’t appear to see any end in sight: in fact, more expect capacity constraints in the next five years than are experiencing them today.

    To better understand what will be leading to these future constraints, we asked respondents to identify the major factors likely to constrain their organization’s production capacity during the next five years. Clear winners are showing up.

    The most frequently indicated factor, by a large margin, was facility constraints, with 52.9% of our respondents citing this as a cause of future capacity problems. This factor is likely emerging as existing facilities age or become obsolete.  Single-use and new flexible facility options are creating a set of expectations that mean older facilities are unlikely to survive in their current configurations.  Beyond facility constraints, the second tier factors included: capacity of downstream purification equipment (35.5% of respondents), costs associated with downstream purification (32.3%), analytical testing and drug product release (29.7%), and the inability to hire new, experienced technical and production staff (22.6%).

    Rounding out the top 10 factors creating future capacity constraints were:
    • ‘Inability to retain experienced technical and production staff’ (22.6%),
    • ‘Lack of financing for production expansion’ (21.3%),
    • ‘Inability for any new, cutting edge technology to achieve claimed performance’ (21.3%),
    • ‘Inability to hire new, experienced scientific staff’ (20%), and
    • ‘Inability to obtain raw material required for production’ (18.7%).

    These factors suggest that the industry expects a very broad range of issues to emerge in the future. Few common groups of factors appear, indicating that solutions will also need to be broad ranging.


    Shifts Over Time
    Study data for this year show significant differences from previous years. The top factor, ‘facility constraints,’ maintained its dubious distinction from the previous two years, increasing from 48.6% of respondents last year, but down from a peak of 55.4% in 2010. Beyond this consistent top factor, though, perceptions have tended to differ over time.

    The #2 factor, this year, ‘physical capacity of downstream purification equipment,’ increased 7.4% points from last year, when it stood in the third position, but below 2010’s high of 41.7% (and the #2 spot). By now, the lack of capacity in the downstream purification area is a well-known capacity constraint; it is affected by increasing titers and improvements in upstream production. This is clearly identified in the data — the 35.5% indicating this to be a ‘future factor’ this year, although lower than the peak concerns last year, continues to be an ongoing worry.
    The lack of technological evolution in purification, filtration and chromatography means that biomanufacturing facilities continue to struggle with downstream processing bottlenecks. These constraints are difficult to correct, requiring alternatives to current chromatography steps, more efficient columns and buffer prep and hold space that is capital intensive.

    This year’s #3 factor, ‘costs associated with downstream purification,’ took a big jump from last year’s 23.3% to this year’s 32.3%, and is at a five-year peak. Back in 2006-07, ‘inability to hire new, experienced technical and production staff’ topped the list of future constraint factors with more than 30.0% of respondents citing this. In 2008, hiring concerns declined in importance to the second constraint slot, with 27.9% of respondents. Worries about technical and production staff hiring largely settled in recent years, and have not reached the level seen in 2004, when this factor was the #1 concern, at 52%.

    Meanwhile, the ‘inability for any new cutting edge technology to achieve claimed performance’ rose markedly this year to 21.3% of respondents indicating it as a future concern, after holding steady around 12.5% between 2008 and 2012. This ties back to the issue of downstream purification, as there appear to be no significant advances in technology in this area that would allow the alleviation of this capacity constraint.

    Also growing this year was the ‘inability to obtain raw materials required for production,’ which has been on a steady increase, increasing from 5.2% of respondents in 2008 to 10.0% last year, before jumping to 18.7% this year and breaking into the top 10. Just five years ago, this was one of the least-cited concerns.  This may be the result of significantly increased focus on secure sourcing, and the traceability of materials.

    People-Based Problems
    The industry this year appears to be less concerned with a number of “people-based” factors that affect capacity. As noted above, ‘inability to hire new, experienced technical and production staff’ dropped three spots on our list this year as a future capacity factor; other people-factors also decreased. For example, ‘inability to hire new, experienced scientific staff’ (20.0% this year vs. 27.6% last year) and ‘inability to retain experienced scientific staff’ (16.8% this year vs. 21.4% last) both saw fairly significant drops, while the ‘inability to retain experienced technical and production staff’ saw only a marginal increase, from 21.4% last year to 22.6% this year.

    While the data suggests that people-based constraints (both in terms of hiring and retaining talent) have become less of an issue in 2012, they still feature among the top concerns held by biomanufacturers. One of the primary reasons is that much of the knowledge in the biotech community is institutional in nature, and largely based in the U.S. and Europe. Experienced operators mitigate contamination risks and provide a depth of production experience that can be used to reduce costs and cycle times.

    People Problems at CMOs
    For CMOs (particularly those in Asia) looking to move into the biomanufacturing space, the people-based constraints may be a significant challenge. In fact, when we separate responses into two groups — biotherapeutic developers only and CMOs only — we find that, while CMOs expressed much higher levels of concern for most factors, in general CMOs were more concerned over hiring issues than biotherapeutic developers were. For example, CMOs were far more likely than biodevelopers to believe that the ‘inability to hire new, experienced technical and production staff’ would create future capacity constraints (40.0% vs. 25.9%). They were similarly more apt to demonstrate concern with the ‘inability to hire new, experienced scientific staff’ (30.0% vs. 18.5%) and the inability to retain this staff (25.0% vs. 15.6%).

    That is not to say that biodevelopers do not have staffing concerns, too: they still occupy three of their top 10 factors. Yet CMOs are an important leading indicator for concerns because they retain a tight focus on operations, and are critically focused around managing cost and efficiency for the products they are producing, whereas biodevelopers are more likely to take a longer view of the process. In the next three to four years, then, we might expect to see experienced people — particularly in the operations and late-stage process development community — become increasingly valuable, particularly as the industry pivots towards lower-cost manufacturing of biogenerics, where cycle times and avoiding contamination events are critically important. Indeed, while biomanufacturers traditionally have had a relatively open culture towards sharing best practices and techniques in the industry, the competition brought about by biogenerics could erode some of this camaraderie. With this type of evolution ahead, experienced operations and technical staff become increasingly important to retain – if for no other reason than to prevent the loss of that knowledge to a competitor.


    Regional Differences: U.S. vs Western Europe
    Expectations regarding future capacity-constraint factors showed some significant differences between U.S. and western European respondents (biodevelopers and CMOs combined). In particular, this year, U.S. respondents displayed a higher degree of concern about capacity than their European counterparts. This ties back to separate results from our study, in which 54.5% of U.S. respondents said they expected at least moderate capacity constraints by 2017, compared to just 31.0% of Western European respondents who felt that way.

    One issue for which both groups find a problem is ‘facility constraints,’ which topped the list of factors creating future constraints for both U.S. (54.9%) and western European (54.1%) respondents. Beyond this commonly-held belief, though, opinions begin to differ, notably for the following factors:
    • ‘Physical capacity of downstream purification equipment,’ 30.8% of U.S. vs. 40.5% of European respondents (compared to 33.1% and 22.8% last year, respectively),
    • ‘Inability to retain experienced technical and production staff,’ 26.4% of U.S. vs. only 8.1% of European respondents,
    • ‘Inability to hire experienced technical and production staff,’ indicated by 29.7% of U.S. respondents vs. 18.6% of European respondents, and
    • ‘Inability to optimize my overall system, given my current technology and resources’ 22.0% of U.S. respondents vs 13.5% of European respondents.

    The Road Ahead
    Our study indicates that the biopharmaceutical industry doesn’t see the problem of capacity constraints going away in the next five years. However, the breadth of problem areas suggests there are no clear, singular solutions.  Even so, there is a silver lining: when we examine the data on a multi-year basis, it appears that more facilities are projecting only “minor” or “moderate” constraints going forward, as the decline in facilities expecting “significant” or “severe” constraints continues.

    The industry is indicating that for capacity problems to abate, downstream purification must be a top priority. The relatively tight labor market — particularly for experienced bioprocessing specialists — will also need to be navigated. As the industry addresses downstream purification and human capital issues the capacity problems of the future will continue to abate.

    Reference:
    1. 9th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production: A Survey of Biotherapeutic Developers and Contract Manufacturing Organizations, BioPlan Associates, April 2012.


    Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a biotechnology and life sciences custom marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing”, and many other industry reports. He can be reached at elanger@bioplanassociates.com, 301-921-5979 and www.bioplanassociates.com.

    Survey Methodology: The 2012 Ninth Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production in the series of annual evaluations by BioPlan Associates, Inc. yields a composite view and trend analysis from 302 responsible individuals at biopharmaceutical manufacturers and contract manufacturing organizations (CMOs) in 29 countries. The methodology also included 185 direct suppliers of materials, services and equipment to this industry. This year's survey covers such issues as: new product needs, facility budget changes, current capacity, future capacity constraints, expansions, use of disposables, trends and budgets in disposables, trends in downstream purification, quality management and control, hiring issues, and employment. The quantitative trend analysis provides details and comparisons of production by biotherapeutic developers and CMOs. It also evaluates trends over time, and assesses differences in the world's major markets in the U.S. and Europe.
    Related Searches
    • Analytical Development
    • Process Development
    • cGMP
    • Development
    Suggested For You
    Opportunities in Synthetic Biology Opportunities in Synthetic Biology
    eTheRNA Extends mRNA Production Services eTheRNA Extends mRNA Production Services
    Vetio Animal Health Vetio Animal Health
    Current Trends in Analytical Testing Current Trends in Analytical Testing
    CMOs & Biosimilars Mfg. in the U.S. CMOs & Biosimilars Mfg. in the U.S.
    CMOs Hiring Constraints:  Cell Therapy Manufacturing Expecting Future Challenges CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges
    Year-End Trends in Biopharma Contract Manufacturing Year-End Trends in Biopharma Contract Manufacturing
    Economics of In-House  Buffer Preparation Economics of In-House Buffer Preparation
    2015 in Review: 6 Key Trends Affecting CMOs 2015 in Review: 6 Key Trends Affecting CMOs
    CMOs Are Willing to Pay for More Innovation CMOs Are Willing to Pay for More Innovation
    CMOs Facing Significant Capacity Constraints CMOs Facing Significant Capacity Constraints
    Bio-CMO Capacity Constraints Bio-CMO Capacity Constraints
    Fill-Finish Innovation Fill-Finish Innovation

    Related Bio News & Views

    • Biologics, Proteins, Vaccines | Biosimilars | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development

      CMOs Demanding More Innovations

      Chromatography and single-use equipment top list
      Eric Langer , BioPlan Associates 11.13.13

    • Biologics, Proteins, Vaccines | Capsules | Clinical Trial Materials | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Lyophilization | Methods Development | Parenterals | Process Development | QA/QC | Validation

      How Far Do You Go?

      ...
      Victor A Vinci, Ph.D., Cook Pharmica 06.05.13

    • Analytical Services | Bioanalytical Services | Bioassay Development | Biologics, Proteins, Vaccines | Capsules | Cleaning Validation | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Lyophilization | Process Development | Process Validation | Regulatory Affairs | Scale-up/Technology Transfer | Toxicology | Validation

      The FDA Says You Are Responsible

      . . . But do you know who you are?
      E. Morrey Atkinson, Ph.D., Cook Pharmica 05.04.12


    • Bio News | Biologics, Proteins, Vaccines | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development
      Industry Adopting More Complex Devices

      Industry Adopting More Complex Devices

      CMOs are spending twice as much as bio-innovators on single-use devices
      Eric S. Langer, BioPlan Associates, Inc. 03.07.12

    • Biologics, Proteins, Vaccines | Capsules | Drug Development | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development | R&D | Scale-up/Technology Transfer

      Whose Platform Is It Anyway?

      Both Sides of the Table
      E. Morrey Atkinson, Ph.D. 01.23.12

    • Biologics, Proteins, Vaccines | Extractables and Leachables | Facilities | GMPs/GCPs | Methods Development | Process Development | Process Validation | QA/QC | Validation

      Why Not Do an Engineering Lot?

      Both Sides of the Table – A discussion of CMO/client perspectives
      E. Morrey Atkinson. Ph.D. 10.11.11


    • Biologics, Proteins, Vaccines | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development | Scale-up/Technology Transfer | Validation
      Bio-Outsourcing On the Rise

      Bio-Outsourcing On the Rise

      Fewer companies go 100% in-house
      Eric S. Langer 09.07.11

    Trending
    • Spark Therapeutics Appoints CTO
    • Inside A Vaccine Trial
    • Catalent Acquires Delphi Genetics
    • Wavelength Pharmaceuticals Acquires Majority Stake In Vanamali Organics
    • Pfizer Selects Seven Bridges To Support RNA Sequencing Data
    Breaking News
    • Spark Therapeutics Appoints CTO
    • Cryoport Launches ESG Program
    • U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    • Thermo Fisher Scientific Completes Mesa Biotech Acquisition
    • Ashfield Engage, Popit Form Digital Monitoring Collaboration
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Preliminary Study Links Markers of Impaired Bone Health to Vegan Diet
    Refined Grains Linked to Heart Attack Risk, Early Death
    Kappa Bioscience Extends Research Partnership For COVID-19 Research
    Coatings World

    Latest Breaking News From Coatings World

    Nippon Paint Marine Wins Korea Export Award
    Universal Display Corporation, PPG Expand Global Production of UniversalPHOLED Materials
    PPG Introduces Premium Iso-free Primer Surfacer, Catalyst
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    January AI Raises $8.8 Million in New Funding
    FDA Clears Ava Fertility Tracking Wearable Device
    First Patient in Europe Treated With Diamondback 360 Coronary Orbital Atherectomy System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Spark Therapeutics Appoints CTO
    Cryoport Launches ESG Program
    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Top Beauty Products of 2021, According to HelloGiggles
    Estée Lauder Taps Ana de Armas as Global Brand Ambassador
    Sephora Announces Significant Expansion
    Happi

    Latest Breaking News From Happi

    What You're Reading on Happi.com
    Cosmetic Chemical Sales To Post CAGR 5.8% To 2025
    ACI Urges Senate to Approve Regan as EPA Administrator
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Marshall & Bruce Adds Koenig & Bauer Rapida 106 41-Inch Seven-Color Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    FTA converts Forum & INFOFLEX to virtual events
    Xeikon launches two new digital label printing presses
    UFlex adds capacity in packaging films
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Texas Medical Technology Partners with My Protect Kit
    Mexico City Single-Use Plastics Ban Leads to Tampon Shortage
    Believe Diapers Launch in U.S.
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login